Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|9|1|6-7

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.9, Iss.1, 2015-11, pp. : 6-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease)

By  

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 77-77

Bentham Science Publishers

Access to resources Recommend Favorite

Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 33-43

Bentham Science Publishers

Access to resources Recommend Favorite

Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 19-32

Bentham Science Publishers

Access to resources Recommend Favorite

Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 44-53

Bentham Science Publishers

Access to resources Recommend Favorite

Theranostic Applications of Lutetium-177 in Radionuclide Therapy

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 94-101

Bentham Science Publishers

Access to resources Recommend Favorite